Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 224-228

  Takahashi, Hiroyuki ^a   Lu, Wei ^a,d   Watanabe, Masatoshi ^b   Katoh, Takahiko ^c   Furusato, Masakuni ^d   Tsukino, Hiromasa ^c   Nakao, Hiroyuki ^c   Sudo, Akemi ^a   Suzuki, Hiroyoshi ^e   Akakura, Koichiro ^e   Ikemoto, Isao ^a   Asano, Kouji ^a   Ito, Takaaki ^f   Wakui, Shin ^a   Muto, Tomoko ^d   Hano, Hiroshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d KYORIN UNIVERSITY   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Familial prostatic cancer; Mutation; Risk factor; Single nucleotide polymorphism; Tumor suppressor gene

Indexed keywords

ALANINE; LEUCINE; MESSENGER RNA; MICROSATELLITE DNA; SERINE; THREONINE;

AGED; ALLELE; ARTICLE; ASIAN; CANCER RISK; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ELAC2 GENE; EPIDEMIOLOGICAL DATA; ETHNIC GROUP; FAMILIAL CANCER; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY LOSS; HPC2 GENE; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SCREENING TEST; SOMATIC MUTATION; WESTERN HEMISPHERE;

AGED; CASE-CONTROL STUDIES; DNA; DNA, NEOPLASM; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; HYDROLASES; JAPAN; MALE; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141857813     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11347     Document Type: Article

References (18)

1. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-80.
2. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ. et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001;61:6494-9.
3. Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001;68:912-7.
4. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ. Polymorphisms in the prostate cancer susceptibility gene HPC2/ ELAC2 in multiplex families and healthy controls. Cancer Res 2001;61:4982-4.
5. Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA. Tammela TL, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001;61:6038-41.
6. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-9.
7. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001;68:901-11.
8. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802.
9. Takahashi H, Fukutome K, Watanabe M, Furusato M, Shiraishi T, Ito H, Suzuki H, Ikawa S, Hano H. Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. Prostate 2001;47:85-90.
10. Takahashi H, Furusato M, Allsbrook WC, Jr., Nishii H, Wakui S, Barrett JC, Boyd J. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995;55:1621-4.
11. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, Weber BL, LiVolsi VA, Furusato M, Rebane BA, Cardonick A, Benjamin I, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738-41.
12. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, Friedman LS, King MC, Furusato M, LiVolsi VA, Menzin AW, Liu PC, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
13. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998;58:2076-7.
14. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, Jiang R, Messer CJ, Chew A, Han JH, Duan J, Carr JL, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293:489-93.
15. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
16. Cao H, Hegele RA. Single nucleotide polymorphisms of the resistin (RSTN) gene. J Hum Genet 2001;46:553-5.
17. Garcia-Barcelo MM, Lam LC, Ungvari GS, Lam VK, Tang WK. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001;108:671-7.
18. Iwasaki H, Shinohara Y, Ezura Y, Ishida R, Kodaira M, Kajita M, Nakajima T, Shiba T, Emi M. Thirteen single-nucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals. J Hum Genet 2001;46:544-6.